Navigation Links
FDA Reports New Risks Posed by Anemia Drugs
Date:1/3/2008

ESAs can spur faster cancer growth and earlier death, agency says

THURSDAY, Jan. 3 (HealthDay News) -- Two new studies offer further evidence of the health risks posed by the anemia drugs known as erythropoiesis-stimulating agents (ESAs), U.S. officials announced Thursday.

The studies showed that patients with breast or advanced cervical cancer who took the drugs as treatment for chemotherapy-induced anemia died sooner or had more rapid tumor growth than patients not on the drugs, U.S. Food and Drug Administration officials said in a prepared statement.

On Nov. 8, the FDA approved new "black box" warnings on labels of the three ESAs -- Aranesp, Epogen and Procrit. The warnings detailed the dangers to patients with cancer and patients with chronic kidney failure. Those dangers include heart attack, stroke, heart failure and cancer tumor growth and shortened survival, the FDA said.

The drugs had been touted as a treatment to lessen fatigue and improve quality of life among cancer, HIV and other patients with anemia, but the revised label said there was no evidence to back that claim. The label change was the fifth such change since Procrit was approved in 1989, FDA officials said.

Results of the two studies released Thursday were not among the six studies that led to the Nov. 8 label revision. Taken together, all eight studies show more rapid tumor growth or shortened survival when patients with breast, non-small cell lung, head and neck, lymphoid or cervical cancers received ESAs compared to patients who didn't get this therapy, the FDA said.

The FDA said it plans to discuss the new findings and re-examine the risks and benefits of ESAs for patients with chemotherapy-induced anemia at a public advisory committee meeting in the next few months.

"This new information further underscores the safety concerns regarding the use of ESAs in patients with cancer, which FDA addressed in previ
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Lincare Holdings Inc. Reports Intention to File Shelf Registration Statement
2. UCI Medical Affiliates, Inc. Reports Fiscal Year End Results for September 30, 2007
3. The Ensign Group, Inc. Reports Third Quarter 2007 Earnings
4. HealthPartners Reports 2007 Most Cost Effective Programs Reduce Expenses by $74 Million
5. Par Pharmaceutical Reports Third-Quarter 2007 Results
6. Briggs & Riley Reports That More Travelers Focus on Health and Sanitation This Holiday Season
7. Recent Reports Underscore the Importance of Testing Supplements for Athletic Banned Substances
8. Intensive care quality of sleep improved by new drug, reports study
9. Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results
10. IBM reports milestone in silicon nanophotonics
11. Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Reports New Risks Posed by Anemia Drugs
(Date:8/2/2015)... ... ... “would be” entrepreneurs, starting a new business can prove to be daunting from the viewpoint ... needs be a major obstacle. , The U.S. has always been the land of ... The risks of starting a business can be high but the rewards can be well ...
(Date:8/1/2015)... ... , ... Back packs can be dangerous? Whaaat?! , Not the danger that ... on a kid's spine. With school starting again, most kids will be asking for ... are aware of how to help them prevent injuries by understanding backpack safety. , ...
(Date:8/1/2015)... NY (PRWEB) , ... August 01, 2015 , ... Calvary ... scroll currently housed at their Bronx campus. The goal is to bring this Torah ... again be used in Jewish rituals and religious services. , Scroll No. 515, ...
(Date:8/1/2015)... York, NY (PRWEB) , ... August 01, 2015 , ... ... Vine cyberespionage group , who are thought to have been behind the attack on ... the topics covered were zero day exploits, watering hole attacks and spear phishing campaigns. ...
(Date:8/1/2015)... ... 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community ... by stepping off Springer Mountain and heading north. Since that day, Phil has hiked ... and was greeted by friends and family. He visited CCAR and left an inspirational ...
Breaking Medicine News(10 mins):Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2
... Institute researcher Jeff Tyner, Ph.D., has created a way to ... myeloid leukemia using an assay that yields results in just ... Society of Hematology annual meeting in Atlanta, on Monday, Dec. ... assay, called RAPID, because it rapidly delivers the information, has ...
... DIEGO, Dec. 10 ADVENTRX Pharmaceuticals,Inc. (Amex: ... on commercializing proprietary product candidates for the treatment,of ... M. Culley,ADVENTRX,s chief business officer, is scheduled to ... as part of a panel on Better Drugs ...
... Human Resources Professional Brings Diverse Expertise, MIAMI, ... biotherapeutic products to healthcare providers, is pleased,to announce ... Vice President of,Human Resources. Ms. Lopez was most ... & Johnson Company. Her 17-year career began,in Human ...
... States may be less likely to report a family history ... prevention strategies according to a new study. Dr. Heather Orom ... colleagues argue that as a result of being less likely ... as strong a predictor of cancer risk in immigrant populations. ...
... and post-stem cell transplantation results compared to thalidomide and ... ... Pharmaceuticals,Inc. (Nasdaq: MLNM ) reported the presentation of results from ... randomized,Phase III clinical trial. This study compared VELCADE, thalidomide and,dexamethasone (VcTD) ...
... improvement across all ... survival -, ATLANTA, Dec. 9 Millennium Pharmaceuticals,Inc. ... results from the,682 patient, randomized, Phase III VISTA(1) trial. ... for stem cell,transplantation (SCT). The trial compared VELCADE, melphalan ...
Cached Medicine News:Health News:OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia 2Health News:ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference 2Health News:Novis Pharmaceuticals Hires Lisa Lopez 2Health News:Immigrant patients less likely to report family history of cancer 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 3Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 4Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 5Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 6Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 2Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 3Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 4Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 5Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 6Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 7
(Date:7/31/2015)... 2015 According to a new ... (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, ... Analysis & Forecast to 2019", published by MarketsandMarkets, the ... Million 2014 and is estimated to grow to $1,425.7 ... from 2014 to 2019. Browse 41 ...
(Date:7/30/2015)... July 30, 2015  ResMed (NYSE: ... a definitive agreement to acquire Curative Medical, ... and sleep-disordered breathing medical devices and accessories. ... in China, combined with ResMed,s global leadership in sleep and respiratory ... China suffering from sleep-disordered ...
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
Breaking Medicine Technology:Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... March 15, 2012 Reportlinker.com announces that ... in its catalogue: ... http://www.reportlinker.com/p0578259/Vaccines---Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This market research report ... actual market situation, trends and future outlook ...
... March 14, 2012 Brainlab wins coveted ,red dot ... world submitted 4,515 designs altogether to the international product ... received the globally sought after red dot in product ... technology. This advanced surgical navigation system for the brain ...
Cached Medicine Technology:Vaccines - Asia 2Brainlab Curve Wins Coveted Red Dot Award: Product Design 2012 2Brainlab Curve Wins Coveted Red Dot Award: Product Design 2012 3
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
Ruschelit® PVC. Murphy eye-nasoral. Black positioning ring. High volume/low pressure cuff. X-ray opaque line. Graduated. Single use....
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. No cuff.Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Sterile...
Medicine Products: